Please login to the form below

Not currently logged in


This page shows the latest fingolimod news and features for those working in and with pharma, biotech and healthcare.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod

If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only

Latest news

More from news
Approximately 3 fully matching, plus 89 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....
OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward